Filing Flows › Verrica Pharmaceuticals (VRCA) › R&D spending
Verrica Pharmaceuticals (VRCA) R&D spending by quarter
Verrica Pharmaceuticals' R&D spending was $6.0M in Q2 2026 (second quarter 2026), +56% from Q1 2026. Over the last 5 quarters it ranged from $1.8M (Q2 2025) to $6.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $6.0M | +56% | +227% |
| Q1 2026 | $3.9M | +53% | — |
| Q4 2025 | $2.5M | +14% | — |
| Q3 2025 | $2.2M | +19% | — |
| Q2 2025 | $1.8M | — | — |
Q2 2026 at a glance
Verrica Pharmaceuticals, Q2 2026: revenue $5.9M (-54% year over year), operating margin -223.4%, net loss $13.2M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Verrica Pharmaceuticals' R&D spending?
Verrica Pharmaceuticals' R&D spending was $6.0M in Q2 2026 (second quarter 2026), +56% from Q1 2026.
How has Verrica Pharmaceuticals' R&D spending changed?
Over the last 5 quarters it ranged from $1.8M (Q2 2025) to $6.0M (Q2 2026).
Q2 2026 results → · How Verrica Pharmaceuticals makes money →